Alpana Mohta, MD, is a dual board-certified dermatologist, venereologist, and leprologist, with a research focus on immunotherapy for viral diseases and autoimmune disorders. With over 80 publications, Mohta has expertise...
Learn about our editorial policies. Immortalized Lung Epithelial Cell Line
Stay up to date on the latest science with Brush Up Summaries.
Hybridoma technology involves fusing short-lived antibody-producing B cells with immortal myeloma cells, creating cell lines that produce a never-ending supply of a specific monoclonal antibody. The technique was created in 1975 by Nobel prize-winning scientists Georges Kohler and Cesar Milstein.1
Scientists create monoclonal antibodies by cloning a single antibody-producing cell line. In contrast to polyclonal antibodies, monoclonals are highly specific to an antigen. By fusing myeloma cells that can divide indefinitely with B cells that produce specific antibodies against the target of interest, researchers obtain a nearly unlimited source of identical monoclonal antibodies.2
Since 1986, over 117 monoclonal antibodies have been FDA-approved, beginning with the mouse monoclonal antibody Muromonab-CD3 for kidney transplant rejection.3 In additional to antibodies from mice and humans, researcher have produced chimeric and humanized monoclonal antibodies that are composed of sequences from both species. By replacing mouse-derived protein sequences with human ones, these monoclonal antibodies reduce the risk of triggering an immune response in humans.4 Using various methods, scientists have also produced monoclonal antibodies from other mammals for diverse purposes.
Researchers inject a mammal, typically a mouse, with a target antigen, stimulating an immune response. Antigen injection may occur in a series over the course of several weeks. Then, researchers harvest the mouse's spleen to obtain B cells that produce the desired antibody.1
Researchers fuse antibody-producing B cells with myeloma cells in cell culture. Polyethylene glycol (PEG) facilitates fusion of both cells’ plasma membranes, forming a single hybridoma cell with two or more nuclei. Alternatively, electrofusion can merge the cells using a pulsed electrical field.5
Less than 1 percent of the initial cells fuse to form hybridoma cells. Unused B cells in the culture stop dividing naturally, while chemotherapy destroys the unfused myeloma cells. Researchers use HAT (hypoxanthine-aminopterin-thymidine) medium to allow the selective proliferation of immortal monoclonal antibody-producing cell lines. The aminopterin in the HAT medium stops nucleotide synthesis, while hypoxanthine and thymidine can be used by cells, such as B cells, carrying the HGPRT (hypoxanthine-guanine phosphoribosyl transferase) enzyme. Hybridoma cells with functional HGPRT enzyme can survive and grow, while myeloma cells lacking it eventually die.1
Researchers often screen hybridoma cells for the monoclonal antibody of interest using an enzyme-linked immunosorbent assay (ELISA). Indirect ELISAs identify antibodies with the appropriate specificity by immobilizing the antigen on a surface and incubating it with a hybridoma cell supernatant. Researchers also use techniques including western blot, flow cytometry, and immunoprecipitation-mass spectrometry to screen their hybridoma cultures.1
The final step involves cloning desired hybridoma cells to obtain a stable cell population and growing the culture to collect large amounts of monoclonal antibodies. This can be achieved through one of two methods.1
This technology offers numerous advantages, namely1,6
Nevertheless, the technology also has a few limitations.1,7
Owing to their high specificity, the antibodies produced by hybridoma technology have a wide range of diagnostic applications, including the following.
There are various FDA-approved indications of monoclonal antibodies (see table below).3 Common indications include the following.
Prevention of kidney transplant rejection
Prevention of respiratory syncytial virus infection
2. Mitra S, Tomar PC. Hybridoma technology; advancements, clinical significance, and future aspects. J Genet Eng Biotechnol. 2021;19(1):159. doi:10.1186/s43141-021-00264-6
3. Antibody therapeutics approved or in regulatory review in the EU or US. Antibody Society. Accessed March, 2023.
4. Castelli MS, McGonigle P, Hornby PJ. The pharmacology and therapeutic applications of monoclonal antibodies. Pharmacol Res Perspect. 2019;7(6):e00535. doi:10.1002/prp2.535
5. Tabll A, Abbas AT, El-Kafrawy S, Wahid A. Monoclonal antibodies: Principles and applications of immmunodiagnosis and immunotherapy for hepatitis C virus. World J Hepatol. 2015;7(22):2369-2383. doi:10.4254/wjh.v7.i22.2369
6. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–497. doi: 10.1038/256495a0
7. Moraes JZ, Hamaguchi B, Braggion C, et al. Hybridoma technology: is it still useful? Curr Res Immunol. 2021;2:32-40. doi:10.1016/j.crimmu.2021.03.002
8. Sundarraj S, Rajagopal G, Sundaramahalingam B, et al. Methods of Protein Detection in Cancer for Diagnosis, Prognosis and Therapy. Protein Detection. IntechOpen; 2022. doi.org/10.5772/intechopen.101050
9. Mazzulli T. Laboratory Diagnosis of Infection Due to Viruses, Chlamydia, Chlamydophila, and Mycoplasma. Principles and Practice of Pediatric Infectious Disease. 2008;1352-1368. doi:10.1016/B978-0-7020-3468-8.50293-5
10. Centers for Disease Control and Prevention. CDC Yellow Book 2020: Health Information for International Travel. New York: Oxford University Press; 2017.
11. Drain PK. Rapid Diagnostic Testing for SARS-CoV-2. N Engl J Med. 2022;386(3):264-272. doi:10.1056/NEJMcp2117115
Alpana Mohta, MD, is a dual board-certified dermatologist, venereologist, and leprologist, with a research focus on immunotherapy for viral diseases and autoimmune disorders. With over 80 publications, Mohta has expertise...
Stem Cells And Immortality © 1986–2024 The Scientist. All rights reserved.